世界领先的临床前神经科学经验
For more than 30 years, in collaboration with some of the best partners in the world, Atuka’s scientists have continued to advance both knowledge and research techniques in the field of Parkinson’s disease and beyond. This has led to the development of the broadest range of preclinical animal models for Parkinson’s disease.
科学的背后
Aligning in vivo models of Parkinson’s disease with biological classifications
A free short video lecture from Atuka’s Chief Innovation Officer Dr. Patrick Howson, on the reasons why Parkinson’s research has delivered symptomatic therapies but no disease-modifying ones, and how biological classification can align models to disease process.
The importance of data management in ensuring the integrity of biomedical research
From data handling and analysis to transparent reporting protocols, EQIPD guidelines are helping to ensure researchers generate more robust and reliable data.
Towards a cure, through collaboration and clarity: Perspectives from the 2025 MJFF Therapeutics Conference
How researchers, clinicians, and companies are reading the current moment in Parkinson’s Research.
A quality system that boosts both research integrity and innovation
Unlike other quality systems, EQIPD has been designed to spur innovation in research without sacrificing rigor.
Better data, better reproducibility: the importance of quality systems
Patrick Howson on constantly improving Atuka’s quality system and the value of EQIPD.
Listening to patients, leading with science
A conversation with Peter DiBiaso on how patient voices can shape real progress in Parkinson’s research, moving us from token listening to actionable science.
Expanding frontiers in neuroimmunology
Jon Brotchie 分享了近期在波士顿举行的神经免疫药物开发峰会的一些精彩要点，特别是关于 TREM2 如何逐渐成为帕金森疾病最有前景的新靶点之一，包括在作用机制方面和目前可用于调控它的多种潜在方法。
白皮书
Redefining Parkinson’s Disease
A primer on the emerging biological understanding of Parkinson’s and its possible impact on the development of novel therapeutics and disease modelling.
发现系列
#3 – LRRK2
Leucine-rich repeat kinase 2 (LRRK2)-targeted
therapies for the treatment of Parkinson’s disease
白皮书
从临床前角度看基因疗法的未来
基因疗法的潜力终于得到了发挥，这些疗法有望为多种疾病带来改变人生的治疗方案。
Atuka 首席创新官 Patrick A. Howson 博士深入探讨了基因疗法的过去、现在与未来。
与我们的专家进行交流
赋能您的研发项目
获取来自 Atuka 的最新科学进展
订阅我们的季刊，了解帕金森疾病研究领域的最新进展。
已发表的论文
Atuka 的科研团队长期致力于神经科学领域的开创性研究，常与领域内其他知名专家合作。我们所发表的系列同行评审论文记录了本公司研究进展与该领域的发展脉络。
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
/ 291 CitationsNovel nondopaminergic targets for motor features of Parkinson’s disease: Review of recent trials
/ 108 Citations- / 21 Citations
- / 27 Citations
l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson’s disease
/ 37 Citations- / 30 Citations
A critique of available scales and presentation of the non‐human primate dyskinesia rating scale
/ 61 Citations- / 41 Citations
- / 41 Citations
Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson’s disease
/ 25 CitationsDihydropyridine calcium channel blockers and the progression of parkinsonism
/ 60 Citations- / 22 Citations
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA
/ 29 CitationsRegulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
/ 21 Citations- / 11 Citations
The serotonergic system in Parkinson’s disease
/ 170 Citations- / 41 Citations
- / 41 Citations
Pros and cons of a prion-like pathogenesis in Parkinson’s disease
/ 13 Citations- / 26 Citations